Cancer Prevention Pharmaceuticals Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 14

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $70.3M

Cancer Prevention Pharmaceuticals General Information

Description

Developer of treatment therapies designed to reduce the risk and recurrence of cancer and rare diseases. The company develops therapeutic agents, diagnostics, and lifestyle recommendations for the treatment of risk factors for cancer and also develops cancer chemoprevention indications for common cancers along with prevention and therapeutic strategies in certain rare cancers, enabling patients and physicians to prevent cancer or the recurrence of cancer by identifying and treating the cancer risk factors early.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1760 East River Road
  • Suite 250
  • Tucson, AZ 85718
  • United States
+1 (520)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1760 East River Road
  • Suite 250
  • Tucson, AZ 85718
  • United States
+1 (520)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cancer Prevention Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 15-Jun-2022 $70.3M Completed Clinical Trials - General
7. Later Stage VC 29-Jan-2021 Completed Clinical Trials - General
6. Later Stage VC 14-Sep-2017 Completed Clinical Trials - General
5. IPO 02-Nov-2016 Cancelled Clinical Trials - General
4. Later Stage VC (Series A2) 31-Oct-2013 Completed Clinical Trials - General
3. Early Stage VC (Series A1) 01-Sep-2012 Completed Startup
2. Accelerator/Incubator 01-Jan-2012 $230K $230K Completed Startup
1. Grant 02-Dec-2010 $240K Completed Startup
To view Cancer Prevention Pharmaceuticals’s complete valuation and funding history, request access »

Cancer Prevention Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2
Series A1
To view Cancer Prevention Pharmaceuticals’s complete cap table history, request access »

Cancer Prevention Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of treatment therapies designed to reduce the risk and recurrence of cancer and rare diseases. The company dev
Drug Discovery
Tucson, AZ
14 As of 2021

East Hanover, NJ

Madison, WI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cancer Prevention Pharmaceuticals Competitors (10)

One of Cancer Prevention Pharmaceuticals’s 10 competitors is Immetas, a Venture Capital-Backed company based in East Hanover, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immetas Venture Capital-Backed East Hanover, NJ
Centrose Venture Capital-Backed Madison, WI
Emtora Biosciences Venture Capital-Backed San Antonio, TX
StemSynergy Therapeutics Venture Capital-Backed Miami, FL
Aura Biosciences Formerly VC-backed Boston, MA
You’re viewing 5 of 10 competitors. Get the full list »

Cancer Prevention Pharmaceuticals Patents

Cancer Prevention Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3235787-A1 Methods of treating patients having type 1 diabetes with eflornithine Pending 02-Nov-2021
US-20260137642-A1 Methods of treating patients having type 1 diabetes with eflornithine Pending 02-Nov-2021
WO-2023081612-A1 Methods of treating patients having type 1 diabetes with eflornithine Inactive 02-Nov-2021
CA-3139162-A1 Methods for treating familial adenomatous polyposis Active 17-May-2019
US-20220040130-A1 Methods for treating familial adenomatous polyposis Inactive 17-May-2019 A61K31/198
To view Cancer Prevention Pharmaceuticals’s complete patent history, request access »

Cancer Prevention Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cancer Prevention Pharmaceuticals Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Arizona Commerce Authority Government Minority
Arizona Tech Investors Angel Group Minority
DVI Equity Partners Venture Capital Minority
Angel (individual) Minority
Desert Angels Angel Group Minority
You’re viewing 5 of 11 investors. Get the full list »

Cancer Prevention Pharmaceuticals FAQs

  • When was Cancer Prevention Pharmaceuticals founded?

    Cancer Prevention Pharmaceuticals was founded in 2008.

  • Where is Cancer Prevention Pharmaceuticals headquartered?

    Cancer Prevention Pharmaceuticals is headquartered in Tucson, AZ.

  • What is the size of Cancer Prevention Pharmaceuticals?

    Cancer Prevention Pharmaceuticals has 14 total employees.

  • What industry is Cancer Prevention Pharmaceuticals in?

    Cancer Prevention Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Cancer Prevention Pharmaceuticals a private or public company?

    Cancer Prevention Pharmaceuticals is a Private company.

  • What is the current valuation of Cancer Prevention Pharmaceuticals?

    The current valuation of Cancer Prevention Pharmaceuticals is .

  • What is Cancer Prevention Pharmaceuticals’s current revenue?

    The current revenue for Cancer Prevention Pharmaceuticals is .

  • How much funding has Cancer Prevention Pharmaceuticals raised over time?

    Cancer Prevention Pharmaceuticals has raised $18.8M.

  • Who are Cancer Prevention Pharmaceuticals’s investors?

    Arizona Commerce Authority, Arizona Tech Investors, DVI Equity Partners, , and Desert Angels are 5 of 11 investors who have invested in Cancer Prevention Pharmaceuticals.

  • Who are Cancer Prevention Pharmaceuticals’s competitors?

    Immetas, Centrose, Emtora Biosciences, StemSynergy Therapeutics, and Aura Biosciences are some of the 10 competitors of Cancer Prevention Pharmaceuticals.

  • When was Cancer Prevention Pharmaceuticals acquired?

    Cancer Prevention Pharmaceuticals was acquired on 15-Jun-2022.

  • Who acquired Cancer Prevention Pharmaceuticals?

    Cancer Prevention Pharmaceuticals was acquired by Panbela Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process